Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib
Endocrinology and Metabolism · 2024
DOI: 10.3803/enm.2023.1854 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Endocrinology and Metabolism, 2024. Verfasst von Chae A Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Phenylurea Compounds, Thyroid Neoplasms, Quinolines, Iodine Radioisotopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
Background
Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), serve as valuable prognostic indicators in various cancers. This multicenter, retrospective cohort study assessed the treatment outcomes of lenvatinib in 71 patients with radioactive iodine (RAI)-refractory thyroid cancer, considering the baseline inflammatory biomarkers.
Methods
This study retrospectively included patients from five tertiary hospitals in Korea whose complete blood counts were available before lenvatinib treatment. Progression-free survival (PFS) and overall survival (OS) were evaluated based on the median value of inflammatory biomarkers.
Results
No significant differences in baseline characteristics were observed among patients grouped according to the inflammatory biomarkers, except for older patients with a higher-than-median NLR (≥2) compared to their counterparts with a lower NLR (P= 0.01). Patients with a higher-than-median NLR had significantly shorter PFS (P=0.02) and OS (P=0.017) than those with a lower NLR. In multivariate analysis, a higher-than-median NLR was significantly associated with poor OS (hazard ratio, 3.0; 95% confidence interval, 1.24 to 7.29; P=0.015). However, neither the LMR nor the PLR was associated with PFS. A higher-than-median LMR (≥3.9) was significantly associated with prolonged OS compared to a lower LMR (P=0.036). In contrast, a higher-than-median PLR (≥142.1) was associated with shorter OS compared to a lower PLR (P=0.039).
Conclusion
Baseline inflammatory biomarkers can serve as predictive indicators of PFS and OS in patients with RAI-refractory thyroid cancer treated with lenvatinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Korea.
- Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
- Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Kim, C. A., Kim, M., Jin, M., Kim, H. K., Jeon, M. J., Lim, D. J., Kim, B. H., Kang, H. C., Kim, W. B., Shin, D. Y., & Kim, W. G. (2024). Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2023.1854
Vancouver
Kim CA, Kim M, Jin M, Kim HK, Jeon MJ, Lim DJ, et al. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib. Endocrinology and Metabolism. 2024. doi:10.3803/enm.2023.1854
BibTeX
@article{Kim2024,
author = {Kim, Chae A and Kim, Mijin and Jin, Meihua and Kim, Hee Kyung and Jeon, Min Ji and Lim, Dong Jun and Kim, Bo Hyun and Kang, Ho-Cheol and Kim, Won Bae and Shin, Dong Yeob and Kim, Won Gu},
title = {Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib},
journal = {Endocrinology and Metabolism},
year = {2024},
doi = {10.3803/enm.2023.1854}
}
EUVIMED